Developing predictive biomarkers for early disease detection
Administrative Core
['FUNDING_OTHER'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11081757
This study is working on developing reliable tests that can help find cancer early, so patients can get the right treatment sooner, and it brings together different cancer centers to share information and improve these tests.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11081757 on ClinicalTrials.gov |
What this research studies
This research focuses on creating and validating highly predictive biomarkers that can be standardized into clinical assays for early disease detection. The project aims to establish a robust infrastructure for data integration and collaboration among various cancer centers and laboratories. By coordinating efforts and sharing findings, the research seeks to enhance the accuracy and efficiency of biomarker development, ultimately improving patient outcomes. Patients may benefit from advancements in early detection methods that could lead to timely interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for diseases that can be detected through biomarker testing.
Not a fit: Patients with conditions that do not involve detectable biomarkers or those not at risk for the targeted diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and earlier detection of diseases, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown success in developing predictive biomarkers for early disease detection, indicating a promising avenue for this approach.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SEGAL, LEOPOLDO NICOLAS — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: SEGAL, LEOPOLDO NICOLAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center